natgillin/translations-raw huggingface dataset:
Cladribine tablets for use according to any of the preceding claims, wherein the Cladribine tablets are to be administered in combination with interferon-beta. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi, ili upotreba, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što farmaceutsku formulaciju treba primijeniti u kombinaciji s interferonom-B.
A composition comprising the isolated antibody, antigen-binding portion or antibody fragment which binds an epitope on human CADM1 of claim 1 or claim 2 and a pharmaceutically acceptable carrier. 
4. - Supstancija koja sadrži izolirano antitijelo, dio koji veže antigen ili fragment antitijela koji veže epitop na ljudski CADMI sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2 i farmaceutski prihvatljivog nosača.
Usually, a decreasing salt gradient is used to elute samples from the column. 
Uobičajeno, opadajući gradijent soli se koristi kako bi se isprali uzorci iz kolone.
wherein: is C1 to C10 alkyl or arylalkyl; said base catalyst is preferably selected from the group consisting of alkaline hydroxide, carbonate, and phosphate bases; and 
Postupak u skladu s patentnim zahtjevom 26, naznačen time što navedeni bazni katalizator se bira iz skupine koju čine alkalne hidroksidne, karbonatne i fosfatne baze.
The pharmaceutical bag according to claim 7, wherein the cytotoxic drug is selected from the group consisting of: azacytidine, belinostat, bendamustine, brentuximab vedotin, bleomycin, bortezomib, busulfan, carboplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, deferoxamine, doxorubicin, epirubicin hydrochloride, fludarabine, fotemustine, fulvestrant, gemcitabine, idarubicin, ifosfamide, irinotecan hydrochloride, ixabepilone, melphalan, methotrexate, oxaliplatin, paclitaxel, pemetrexed, pentostatin, raltitrexed, romidepsin, temozolomide, thiotepa, topotecan, trabectedin, trastuzumab, and vinblastine. 
Farmaceutska vrećica u skladu s patentnim zahtjevom 8, naznačena time, da je citotoksični lijek odabran iz skupine koju tvore: azacitidin, belinostat, bendamustin, brentuksimab vedotin, bleomicin, bortezomib, busulfan, karboplatin, ciklofosfamid, citarabin, dakarbazin, daktinomicin, daunorubicin, decitabin, deferoksamin, doksorubicin, epirubicin hidroklorid, fludarabin, fotemustin, fulvestrant, gemcitabin, idarubicin, ifosfamid, irinotekan hidroklorid, iksabepilon, melfalan, metotreksat, oksaliplatin, paklitaksel, pemetreksed, pentostatin, raltitreksed, romidepsin, temozolomid, tiotepa, topotekan, trabektedin, trastuzumab i vinblastin.
obtaining a network of chemically interconnected crystalline carbon nanostructures. The method according to claim 1, wherein the bicontinuous micro-emulsion comprises at least 15 nM metal nanoparticles calculated on the aqueous phase. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što dvokontinualna mikroemulzija sadrži najmanje 15 mM metalnih nanočestica, obračunato na vodenu fazu.
The process according to claim 16, wherein the chiral phosphine ligand (D) is selected from the compound of formula (D1). 
Postupak u skladu s patentnim zahtjevom 9 ili 13, naznačen time, da kiralni fosfinski ligand (D) je (S)-BINAP.
In some embodiments, the VEGF/DLL4-binding agent is a bispecific antibody which comprises a first human IgG2 constant region with amino acid substitutions at positions 249 and 288, wherein the amino acids are aspartate, and a second human IgG2 constant region with amino acid substitutions at positions 236 and 278, wherein the amino acids are lysine. 
Bispecifično protutijelo prema bilo kojem od zahtjeva 1 do 11, naznačeno time, da obuhvaća prvo ljudsko konstantno područje IgG2 s aminokiselinskim supstitucijama na pozicijama koje odgovaraju pozicijama 249 1 288 HR P20190044 T1 od SEQ ID NO: 42, pri čemu su aminokiseline zamijenjene s glutamatom i aspartatom, i drugo ljudsko konstantno područje IgG2 s aminokiselinskim supstitucijama na pozicijama koje odgovaraju pozicijama 236 i 278 od SEQ ID NO: 42, pri čemu su aminokiseline zamijenjene s lizinom.
Serine (S) or Threonine (T) at heavy chain amino acid position 103; and/or 
serin (S) ili treonin (T) na aminokiselinskoj poziciji 103 jakog lanca; i/ili
Typically, the daily dose will be 1-100 mg/kg body weight daily. 
Tipično, dnevna doza biti će 1-100 mg/kg tjelesne težine na dan.
is a group of the formula where # is the attachment site to the uracil nitrogen atom, 
# je mjesto spajanja na dušikov atom na uracilu, E! je CR" ili N, gdje
Their aqueous solutions are less acid than those of the corresponding chlorides: consequently these salts are also more suitable for manufacturing injectable administration forms. 
Njihove vodene otopine su manje kisele nego odgovarajući kloridi: zbog toga su te soli također prikladnije za proizvodnju oblika koji se mogu dati u obliku injekcije.
The compound according to claim 1, wherein R8 represents a —O—P(O)(O−)(OR10) group in which R10 represents a hydrogen atom, a benzyl group or a methyl group. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da R8 predstavlja -O- P(O)(O-)(OR10) skupinu u kojoj R10 predstavlja atom vodika, benzilnu skupinu ili metilnu skupinu.
adjusting the pressure in a space between the molding wall and the air-tight covering to a first value, lower than that of the ambient pressure, for creating a reduced pressure in the reinforcement package; 
- < namještanje pritiska u prostoru između stijenke kalupa i neprodušnog pokrova na prvu vrijednost, nižu od vrijednosti pritiska okoline, za stvaranje smanjenog pritiska u tijelu za ojačanje;
A waterside leisure facility according to any of the preceding claims, wherein one or more of the dividing wall and/or the bottom wall portion comprises at least one compliant portion for allowing wave energy to pass through the dividing wall or floor of the enclosure. 
Obalni objekt za odmor u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu jedan ili više pregradnih zidova (104; 204; 304; 404; 504; 604) ili donjih dijelova zida obuhvaća najmanje jedan popustljivi dio koji omogućava prolazak energije valova kroz pregradni zid (104; 204; 304; 404; 504; 604) ili pod prostorije (100; 200;
Fig. 25 shows an automated packing machine (Ilsemann) for packing a packaging 2 according to the invention. 
Slika 25 prikazuje automatizirani stroj za pakiranje (IIsemann) koji služi za pakiranje onih pakiranja 2 koja su u skladu s ovim izumom.
The pyridine derivative or the pharmaceutically acceptable salt thereof, or the solvate thereof according to clause 11, wherein R3 is a hydrogen atom, a methyl group, an ethyl group, an isopropyl group, a cyclopropyl group, a chlorine atom, a bromine atom, an iodine atom, a trifluoromethyl group, a difluoromethyl group, a methoxy group, a phenyl group, a cyano group, an acetyl group, a carboxyl group, -CO2R5, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxypropan-2-yl group, a 3-hydroxypentan-3-yl group, a dimethylaminomethyl group, a diethylaminomethyl group, or a morpholin-4-ylmethyl group. 
Derivat piridina ili njegova farmaceutski prihvatljiva sol, ili njegov solvat prema zahtjevu 9, naznačen time da Rz je vodikov atom, metilna skupina, etilna skupina, izopropilna skupina, ciklopropilna skupina, klorov atom, bromov atom, jodov atom, trifluorometilna skupina, difluorometilna skupina, metoksi skupina, fenilna skupina, cijano skupina, acetilna skupina, karboksilna skupina, -CO>R5, hidroksimetil skupina, 1-hidroksietil skupina, 2hidroksipropan-2-il skupina, 3-hidroksipentan-3-il skupina, dimetilaminometil skupina, dietilaminometilna skupina, ili morfolin-4-ilmetil skupina.
wherein R4b and R5b are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group. 
(2) heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, Ci. alkilnom skupinom, halogen-Ci.s alkilnom skupinom, C1.g alkoksi skupinom ili halogen-C1.4 alkoksi skupinom; i
The subject may exhibit one or more of: (a) a reduction in triglyceride level of at least about 30% as compared to baseline; (b) no increase in non-HDL-C levels as compared to baseline; (c) no decrease in HDL-C levels compared to baseline; and/or (d) a less than 30% increase in LDL-C levels as compared to baseline. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što subjekt pokazuje jedno ili više od sljedećeg: (a) snižavanje razina triglicerida od najmanje otprilike 30% u usporedbi s osnovnim vrijednostima; (b) nulto povišavanje razina ne-HDL-C u usporedbi s osnovnim vrijednostima; (c) nulto snižavanje razina HDL-C u usporedbi s osnovnim vrijednostima; i/ili (d) povišavanje razina LDL-C manje od 30% u usporedbi s osnovnim vrijednostima.
The present compounds are useful for treating a variety of indications, including but not limited to respiratory-tract disorders such as chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis. Muscarinic Receptor Radioligand Binding Assays 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time se što bolest bira iz skupine koju čine kronična opstruktivna plućna bolest, kronični bronhitis, astma, kronična začepljenost dišnih puteva, plućna fibroza, plućni emfizem i alergijski rinitis.
by complexing them with urea and then fractioning/removing the saturated and monounsaturated components, by means of procedures already well-known to the expert by many decades (see Swern D, Techniques of Separation—Urea Mixtures, in “Fatty Acids”, part 3, Ed. 
njihovim kompleksiranjem s ureom i zatim frakcioniranjem/uklanjanjem zasićenih i mononezasićenih komponenata, postupcima koji su već dobro poznati stručnjacima desetljećima (vidi Swcern D, Techniques of Separation - Urca Mixturcs, u "Fatty Acids", dio 3, Izd.
The filtrate was evaporated in vacuo, a further 2.5 L of acetone added and the mixture filtered again. 
Filtrat se otpari u vakuumu, doda još 2,5 1 acetona, a smjesu ponovno filtrira.
mixing the active ingredient pramipexole or a pharmaceutically acceptable salt thereof with either a portion of the fillers or all the excipients in a mixer, wherein pramipexole or the pharmaceutically acceptable salt thereof is milled prior to use; 
(1) miješanje aktivnog sastojka pramipeksola ili njegove farmaceutski prihvatljive soli ili s obrokom punila ili sa svim pomoćnim sredstvima u mješalici, pri čemu su pramipeksol ili njegova farmaceutski prihvatljiva sol mljeveni, povoljno je mljeveni u klinastom mlinu prije uporabe;
A compound, or a pharmaceutically acceptable salt thereof, seleceted from the group consisting of the compounds set forth in the following table: 
Spoj ili njegova farmaceutski prihvatljiva sol, naznačeni time da su odabrani iz skupine koja se sastoji od spojeva prikazanih u slijedećoj tablici: [image] [image] [image] [image]
The box-shaped collar (2) is composed of four perpendicular walls with the same height and has a front opening bordered by the front edges (2a) of the walls and a back opening bordered by the back edges of the said walls. 
Okvir koji ima oblik kutije (2) je sastavljen od četiri okomite stijenke koje imaju jednaku visinu, a kutija ima prednji otvor koji je omeđen s prednjim rubovima (24) stijenki i stražnji otvor koji je omeđen sa stražnjim rubovima navedenih stijenki.
The process of claim 4, wherein the solution is 33% hydrobromic acid in acetic acid. The process of any one of claims 1-5, further comprising a step of pretreating the solution with a bromine scavenger in order to remove free bromine. The process of claim 6, wherein the bromine scavenger is phenol. 
Postupak prema patentnom zahtjevu 4, naznačen time, da otopina bromovodične kiseline u octenoj kiselini jest 33%-tna bromovodična kiselina u octenoj kiselini. Postupak prema bilo kojem od patentnih zahtjeva 1-5, naznačen time, da hvatač broma jest fenol.
determining the first cutoff value from the expected value of the parameter; comparing the parameter to the first cutoff value; and 
Postupak prema zahtjevu 1, naznačen time, da parametar predstavlja omjer sekvenci koje imaju podrijetlo iz prvog kromosoma.
Thus, the composition is useful for diagnosing or treating inflammatory arthritides and connective tissue diseases such as reactive arthropathies, postinfective arthropathies, inflammatory polyarthropathies, systemic connective tissue disorders, inflammatory spondylopathies, myositis, synovitis, Reiter's disease, seropositive rheumatoid arthritis, other rheumatoid arthritis, extraarticular rheumatoid disease, psoriatic and enteropathic arthropathies, juvenile arthritis, unspecified arthritis, polyarteritis nodosa and related conditions, other necrotizing vasculopathies, dermatopolymyositis, systemic sclerosis, other diseases with systemic involvement of connective tissue, ankylosing spondylitis and other inflammatory spondylopathies. 
Farmaceutski pripravak za uporabu prema zahtjevu 18, gdje su spomenuti artritis i bolest vezivnog tkiva izabrani iz skupine koja se sastoji od reaktivnih artropatija, postinfektivnih artropatija, upalnih poliartropatija, sustavnih bolesti vezivnog tkiva, upalnih spondilopatija, miozitisa, sinovitisa, Reiterove bolesti, seropozitivnog reumatoidnog artritisa, reumatoidnog artritisa, ekstraartikularne reumatske bolesti, psorijatskih 1 enteropatskih artropatija, juvenilnog artritisa, artritisa, poliarteritisa nodoze i srodnih stanja, nekrotizirajućih vaskulopatija, dermatopolimiozitisa, sustavne skleroze, sustavnog zahvaćenja vezivnog tkiva, ankilozantnog spondilitisa i upalnih spondilopatija.
and R25 are taken together with the nitrogen to which they are attached to form a 4- to 7-membered monocyclic heterocycloalkyl group, or a 6- to 10-membered bicyclic heterocyclic group having fused, spiro, or bridged rings, and each R24 and R25 can be optionally substituted; 
i R25 se uzimaju zajedno sa azotom za koji su vezane, kako bi obrazovale monocikličnu heterocikloalkil grupu sa 4 do 7 članova, ili bicikličnu heterocikličnu grupu sa 6 do 10 članova koja ima kondenzirane, spiro, ili premošćene prstenove, i svaka R24 i R25 grupa može biti izborno supstituirana;
The method of claim 1, wherein the H-Ras mutation of said subject comprises an amino acid substitution at a codon selected from the group consisting of G12, G13, and Q61. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu H-Ras mutacija navedenog subjekta sadrži nadomjestak amino kiseline u kodonu izabranom iz grupe koja sadrži G12, G13 1 QGI.
and pharmaceutically acceptable salts, hydrates, N-oxides, or solvates thereof. 
i njihove farmaceutski prihvatljive soli, hidrati, N-oksidi ili solvati.
a protein comprising the amino acid sequence of SEQ ID N°2 modified by deletion, substitution, or insertion of one or more amino acids, and having a fructosyl-transferase activity; and 
(B) protein koji ima aminokiselinski slijed SEQ ID NO:2 modificiran delecijom, supstitucijom ili insercijom jedne ili više aminokiselina, te ima aktivnost fruktozil-transferaze; i
The first and second part may be U-shaped such that the legs of the “U” define sidewalls of the parts, said sidewalls may comprise the protrusions for attaching them to the inner part. 
Prvi i drugi dio mogu imati U-oblik, tako da krakovi slova "U" određuju bočne stijenke ovih dijelova, pri čemu navedene bočne stijenke mogu imati izbočenja radi njihovog pričvršćivanja s unutarnjim dijelom.
A composition having a structure according to formula (IV) D-(XD)aC(XZ)b-R31 (IV) wherein 
Kompozicija koja ima strukturu u skladu sa formulom (IV)
The preferred amount of component a) in the composition is in the range of 0.1 to 15 wt.%, more preferably 0.3 to 15 wt.%, most preferably 0.5 to 10 wt.% by weight of the total composition. 
Poželjna količina sastojka a) u pripravku u rasponu je od 0,1 do 15 težinskih %, poželjno 0,3 do 15 težinskih %, najpoželjnije 0,5 do 10 težinskih % od ukupne težine pripravka.
wherein when the upper intra prediction mode or the left intra prediction mode is unavailable, the upper intra prediction mode or the left intra prediction mode is set to a DC mode. 
Uređaj prema zahtjevu 1, naznačen time da kada je način unutarokvirnog predviđanja horizontalni način, obrazac skeniranja je vertikalni obrazac skeniranja.
a first stream of boil-off gas, which is generated from the liquefied natural gas in the cargo tank and is discharged from the cargo tank; 
prvu struju otparenog plina, nastalog iz ukapljenog zemnog plina u skladišnom spremniku (11), te ispuštenog iz skladišnog spremnika (11);
The method according to claim 1, wherein the disease or disorder is lung cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak jetre.
The method according to claim 15, wherein said bioadhesive polymer is selected from the group consisting of cellulose polymers, natural gums, sodium alginate, polyoxyethylenes, acrylic polymers and mixtures thereof. 
Upotreba u skladu s bilo kojim od prethodnim patentnim zahtjevima, naznačena time što se navedeni bioadhezivni polimer bira iz skupine koju čine celulozni polimeri, prirodne gume, natrijev alginat, polioksietileni, akrilni polimeri i njihove smjese.
The quantity of active ingredient present in the solvent at the particular time of testing was determined by spectrophotometry. 
Količina djelatne tvari, koja se u dotičnom trenutku ispitivanja nalazila u otapalu, određena je spektralnom fotometrijom.
Z represents any of the following substituents, designated Z1 to Z7: 
Z predstavlja bilo koji od slijedećih supstituenata koji su označeni ZI do Z7:
The method of claim 8 wherein the method further comprises the step of reversing the chiral configuration of the chiral carbon in the six-membered saturated ring of the tetrahydronaphthalene moiety that was previously bound to the oxo group by treating Formula VI-R or VI-S with diphenylphosphoryl azide (DPPA) to form an azido tetrahydronaphthalene of Formula VII-S or VII-R: where the azido substituent in the six-membered saturated ring of the tetrahydronaphthalene moiety replacing the hydroxy substituent and the chiral carbon that is bound to the azido substituent has a reverse chiral configuration of the chiral carbon when it was previously bound to the hydroxy substituent. 
OH VI-S, gdje je Z -CN, -Cl ili -CFa. Postupak u skladu s patentnim zahtjevom 8, naznačen time što postupak dodatno uključuje korak reverzije kiralne konfiguracije na kiralnom ugljiku u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka prethodno vezanom na skupinu okso obradom Formule VI-R ili VI-S difenilfosforil-azidom (DPPA) kako bi se dobilo azidotetrahidronaftalen Formule VII-S ili VII-R:
The reaction was allowed to stir while warming to 10ºC. 
Bilo je omogućeno da se reakcijska smjesa miješa za vrijeme zagrijavanja do 100?C.
P1-Har-Gly-Asp(O—P2)-Trp-Pro-ACys-NH2 (SEQ ID NO:4) wherein ACys-NH2 is an activated cysteinamide, through a disulfide linkage between the Mpa and the ACys-NH2 of the 2-7 eptifibatide sequence, thereby forming the compound of formula I. 
P,-Har-Gly-Asp(O-P>2)- Trp-Pro-ACys-NH> gdje je ACyS-NH, aktivirani rezidđuum cisteinamida, putem disulfidne veze između rezidua Mpa i rezidua ACys- NH, fragmenta 2-7 eptifibatida, čime se formira spoj formule I.
The hybrid electric drive unit according to any one of claims 1 to 8, characterized in that the drive disc of the first clutch is directly connected to a rotor support of the second motor. 
Hibridna električna pogonska jedinica prema bilo kojem od zahtjeva 1 do 8, naznačena time, da je pogonski disk prve spojke (6) izravno spojen na nosač rotora (16) drugog motora (3).
wherein R7 is hydrogen or lower alkyl. 
Pri čemu je R' vodik ili niži alkil.
In a separate flask, prepare a 0.25 M aqueous stock solution of p-toluenesulfonic acid. 
U odvojenoj tikvici pripravi se 0,25 M vodena matična otopina p-toluensulfonske kiseline.
Use of (a) a PDE4 inhibitor as defined in any one of claims 1 and 3 to 6 for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 10 or 11. 
Antagonist M3 muskarinskih receptora, za uporabu u skladu sa zahtjevom 16, naznačen time, da pacijent pati od postojećeg stanje srca ili stanja koje će biti pogoršano tahikardijom B2 agonist kako je definirano u patentnom zahtjevu 1 ili 3, naznačen time, da je namijenjen za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s antagonistom M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 1li 2 za liječenje dišnih bolesti kao što je definirano u zahtjevu 7 ili 8.
The beverage of claim 1, wherein Reb X is present in a concentration from 50 to 600 ppm and Mogroside V is present in a concentration from 10 to 250 ppm. 
Napitak prema zahtjevu 1, naznačen time da Reb X je prisutan u koncentraciji od 50 do 600 ppm i Mogrozid V je prisutan u koncentraciji od 10 do 250 ppm.
Another object of the present invention is to provide a sheet for packaging food that is lighter, for an equal format used, than conventional types of sheet. 
Daljnji cilj predloženog izuma je osigurati foliju za pakiranje hrane koja je lakša u usporedbi s upotrijebljenim jednakim formatom konvencionalnih tipova folija.
comprises a light chain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:87; 
slabi lanac koji ima identitet sekvence barem 90% od aminokiselinske sekvence od SEQ ID NO:87.
N-[4-((S)-3-benzylpyrrolidin-1-yl)-2-methylquinolin-6-yl]benzamide, and pharmaceutically-acceptable salts and/or solvates thereof. 
N-[4-((S)-3-benzilpirolidin-1-i1)-2-metilkinolin-6-illbenzamid, i njihove farmaceutski prihvatljive soli i/ili njihovi solvati.
STEP A: dissolving a compound of formula (I-S) in an organic solvent; 
KORAK A: otapanje spoja formule (I-S) u organskom otapalu, pri čemu je organsko otapalo izopropil acetat;
is selected from a divalent arylene, heteroarylene and saturated monocyclic heterocycloalkylene group; 
W, je odabran od dvovalentnog arilena, heteroarilena i zasićene monocikličke heterocikloalkilenske skupine;
The nucleic acid molecule according to claim 26, which is DNA. 
Vektor naznačen time da sadrži molekulu nukleinske kiseline prema zahtjevu 8.
Use of an MTP inhibitor in the manufacture of a medicament for the treatment of a subject suffering from a disorder associated with hyperlipidemia and/or hypercholesterolemia, wherein said treatment comprises the administration of at least three step-wise, increasing dosages of said MTP inhibitor to said subject, and wherein said MTP inhibitor has the structure: or a pharmaceutically acceptable salt thereof or the piperidine N-oxide thereof. 
HR P20130115 T1 PATENTNI ZAHTJEVI Uporaba inhibitora MTP u proizvodnji lijeka za liječenje subjekta koji pati od poremećaja povezanog sa hiperlipidemijom i/ili hiperkolesterolemijom, naznačen time što navedeno liječenje sadrži primjenu najmanje tri postepeno rastuće doze navedenog inhibitora MTP na navedenog subjekta,
A pharmaceutical composition containing cortexolone-17a-propionate in crystalline form I according to any one of claims 17 to 18 in association with at least one physiologically acceptable excipient. 
Farmaceutski pripravak koji sadrži korteksolon-17a-propionat u kristalnom obliku III u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što je navedeni spoj u smjesi s najmanje jednom fiziološki prihvatljivom pomoćnom tvari.
the composition further comprises optionally an amount of about 1 mg of EDTA, and the composition being reconstituted with about 10 ml of water for injection. In this composition the amount of sodium content of the ceftriaxone sodium and the sulbactam sodium is about 132.3 mg with 5.74 mEq of sodium. 
(c) EDTA u količini od 1 mg, spomenuta smjesa je rekonstituirana sa 10 ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznosi 152.3 mg, uz 5.74 mEq natrija.